Oruka Therapeutics (NASDAQ:ORKA) SVP Arjun Agarwal Sells 10,000 Shares

Oruka Therapeutics, Inc. (NASDAQ:ORKA) SVP Arjun Agarwal sold 10,000 shares of the stock in a transaction that occurred on Thursday, August 13th. The shares were sold at an average price of $106.66, for a total transaction of $1,066,600.00. Following the completion of the sale, the senior vice president directly owned 15,312 shares of the company’s stock, valued at approximately $1,633,177.92. This trade represents a 39.51% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Arjun Agarwal also recently made the following trade(s):

• On Monday, July 13th, Arjun Agarwal sold 9,999 shares of Oruka Therapeutics stock. The shares were sold at an average price of $84.63, for a total value of $846,215.37.
• On Monday, June 22nd, Arjun Agarwal sold 1,587 shares of Oruka Therapeutics stock. The stock was sold at an average price of $80.95, for a total value of $128,467.65.
• On Monday, June 15th, Arjun Agarwal sold 395 shares of Oruka Therapeutics stock. The shares were sold at an average price of $69.69, for a total value of $27,527.55.
• On Friday, June 12th, Arjun Agarwal sold 9,459 shares of Oruka Therapeutics stock. The stock was sold at an average price of $69.72, for a total value of $659,481.48.
• On Monday, May 18th, Arjun Agarwal sold 10,290 shares of Oruka Therapeutics stock. The shares were sold at an average price of $59.07, for a total transaction of $607,830.30.

Oruka Therapeutics Stock Performance

Oruka Therapeutics stock opened at $111.04 on Friday. The company has a market capitalization of $7.35 billion, a PE ratio of -54.70 and a beta of -0.34. Oruka Therapeutics, Inc. has a fifty-two week low of $14.08 and a fifty-two week high of $111.37. The firm has a 50 day moving average price of $87.52 and a 200 day moving average price of $62.61.

Oruka Therapeutics (NASDAQ:ORKA) last released its quarterly earnings results on Monday, August 10th. The company reported ($0.55) EPS for the quarter, missing the consensus estimate of ($0.51) by ($0.04). As a group, equities research analysts forecast that Oruka Therapeutics, Inc. will post -2.27 earnings per share for the current year.

Analyst Ratings Changes

Several equities research analysts recently weighed in on ORKA shares. Piper Sandler reaffirmed an “overweight” rating and set a $180.00 target price on shares of Oruka Therapeutics in a research note on Tuesday, June 2nd. Barclays lifted their target price on Oruka Therapeutics from $78.00 to $160.00 and gave the company an “overweight” rating in a report on Monday, April 27th. Wedbush reissued an “outperform” rating and set a $165.00 target price on shares of Oruka Therapeutics in a research note on Tuesday. Leerink Partners set a $120.00 target price on Oruka Therapeutics in a research note on Thursday, April 30th. Finally, Wall Street Zen upgraded Oruka Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, August 8th. Ten analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $134.30.

Hedge Funds Weigh In On Oruka Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in ORKA. BlackRock Inc. acquired a new position in shares of Oruka Therapeutics in the second quarter valued at approximately $474,916,000. Viking Global Investors LP acquired a new stake in Oruka Therapeutics in the third quarter valued at $51,280,000. Paradigm Biocapital Advisors LP purchased a new position in Oruka Therapeutics in the 4th quarter valued at approximately $51,840,000. Remedium Capital Partners LLC acquired a new position in shares of Oruka Therapeutics during the 4th quarter worth $47,054,000. Finally, Jupiter Topco LLC purchased a new stake in shares of Oruka Therapeutics in the second quarter valued at about $130,968,000. Hedge funds and other institutional investors own 56.44% of the company’s stock.

Oruka Therapeutics Company Profile

Oruka Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of novel peptide‐based therapies for oncology. The company’s proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell‐permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”

The company’s lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.